Abstracts tagged "complement and systemic lupus erythematosus (SLE)"

Abstract Number: 1669 • 2018 ACR/ARHP Annual Meeting
iC3b/C3 Ratios More Strongly Correlate with SLE Disease Activity in African-Americans Compared to Whites
Deepali Sen¹, Vibeke Strand², Nancy Mathis³, Qiang Fu⁴ and Alfred Kim⁵, ¹Rheumatology, Washington University School of Medicine, St. Louis, MO, ²Stanford University School of Medicine, Palo Alto, CA, ³Rheumatology, Washington University School of Medicine, Saint Louis, MO, ⁴Epidemiology and Biostatistics, Saint Louis University College for Public Health and Social Justice, Saint Louis, MO, ⁵Medicine/Rheumatology, Washington University School of Medicine, St. Louis, MO
iC3b/C3 Ratios More Strongly Correlate with SLE Disease Activity in African-Americans Compared with WhitesBackground/Purpose: Complement activation is a hallmark of systemic lupus erythematosus (SLE) pathophysiology.…
Abstract Number: 2833 • 2018 ACR/ARHP Annual Meeting
Complement Activation Is a Feature of Diseases in the Lupus Spectrum
Rosalind Ramsey-Goldman¹, Roberta Alexander², Elena Massarotti³, Daniel J. Wallace⁴, Sonali Narain⁵, Cristina Arriens⁶, Christopher E. Collins⁷, Amit Saxena⁸, Chaim Putterman⁹, Kenneth C. Kalunian¹⁰, Armida Sace², Rowena Lafon², Tyler O'Malley², JoAnne Ligayon², Claudia Ibarra², John Conklin², Thierry Dervieux² and Arthur Weinstein⁷, ¹FSM, Northwestern University, Chicago, IL, ²Exagen Diagnostics, Inc., Vista, CA, ³Brigham and Women's Hospital, Boston, MA, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Northwell Health, Great Neck, NY, ⁶Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, ⁸NYU Langone Health, New York, NY, ⁹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ¹⁰Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: We showed previously that complement activation - cell-bound complement activation products (CB-CAPS) or multi-analyte assay panel (MAP) - is a sensitive and specific biomarker…
Abstract Number: 673 • 2017 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products Distinguish Systemic Lupus Erythematosus from Other Diseases Among Patients with High Antinuclear Antibody Titers and Normal Complement
Daniel J. Wallace¹, Elena Massarotti², Rosalind Ramsey-Goldman³, Christopher E. Collins⁴, Anca Askanase⁵, Jill P. Buyon⁶, Richard Furie⁷, Sonali Narain⁷, Amit Saxena⁸, Kenneth C. Kalunian⁹, Cristina Arriens¹⁰, Chaim Putterman¹¹, John Conklin¹², Roberta Alexander¹², Claudia Ibarra¹², Tyler O'Malley¹³, Tarun Chandra¹⁴, Joseph Ahearn¹⁵, Susan Manzi¹⁶, Arthur Weinstein¹⁷ and Thierry Dervieux¹², ¹Cedars-Sinai Medical Center, UCLA, Los Angeles, CA, ²Brigham and Women's Hospital, Boston, MA, ³FSM, Northwestern University, Chicago, IL, ⁴Rheumatology, MedStar Washington Hospital Center, Washington, DC, ⁵Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁶Rheumatology, NYU Langone Medical Center, New York, NY, ⁷Northwell Health, Great Neck, NY, ⁸NYU Langone Medical Center, New York, NY, ⁹Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ¹⁰Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ¹²Exagen Diagnostics, Inc., Vista, CA, ¹³Research and Development, Exagen Diagnostics, Inc., Vista, CA, ¹⁴EmpiriQA LLC, Long Grove, IL, ¹⁵Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁶Medicine, Allegheny Health Network, Pittsburgh, PA, ¹⁷Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC
Background/Purpose: Patients are often referred to the rheumatologist because of elevated anti-nuclear antibody (ANA) titers. We sought to evaluate the association of cell bound complement…
Abstract Number: 681 • 2017 ACR/ARHP Annual Meeting
A Panel of Lupus Biomarkers for the Monitoring of Systemic Lupus Erythematosus: Performance Characteristics in Distinct SLE Cohorts
Joan T. Merrill¹, Thierry Dervieux², Jill P. Buyon³, Rosalind Ramsey-Goldman⁴, Kenneth C. Kalunian⁵, Chaim Putterman⁶, John Conklin², Richard Furie⁷ and Michelle Petri⁸, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Exagen Diagnostics, Inc., Vista, CA, ³Medicine, New York University School of Medicine, New York, NY, ⁴FSM, Northwestern University, Chicago, IL, ⁵Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ⁶Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ⁷Northwell Health, Great Neck, NY, ⁸Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Antibody titers to double stranded DNA (anti-dsDNA) and complement C3 and C4 proteins have clinical utility in the routine monitoring of systemic lupus erythematosus…
Abstract Number: 1673 • 2017 ACR/ARHP Annual Meeting
Human C4 Gene Copy Number Influences Cell-Bound Complement Activation Product (CB-CAP) C4d in Systemic Lupus Erythematosus
Chau-Ching Liu¹, Joseph Ahearn², Amy Xiaoqin Tang², Yee Ling Wu³, CHACK-YUNG Yu³ and Susan Manzi², ¹Lupuc Center of Excellence, Allegheny Health Network Research Institute, Pittsburgh, PA, ²Lupus Center of Excellence, Allegheny Health Network Research Institute, Pittsburgh, PA, ³Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Human complement C4 protein is the product of two isotypic genes C4A and C4B that are located on chromosome 6 in various copy numbers.…
Abstract Number: 1918 • 2017 ACR/ARHP Annual Meeting
Blood Levels of Complement Split Product iC3b and C3 Outperform Traditional Biochemical Measures of SLE Disease Activity in Associating with Active and Clinically Meaningful Changes
Alfred Kim¹, Deepali Sen², Vibeke Strand³, Qiang John Fu⁴, Nancy Mathis¹, Martin Schmidt⁵, Robin Bruchas⁶, Nick Staten⁶, Paul Olson⁶, Chad Stiening⁶ and John Atkinson¹, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, ³Stanford University, Palo Alto, CA, ⁴Biostatistics, Saint Louis University, Saint Louis, MO, ⁵Kypha, Inc., St. Louis, MO, ⁶Kypha, Inc., Saint Louis, MO
Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…
Abstract Number: 2798 • 2016 ACR/ARHP Annual Meeting
Multi-Center Validation of Platelet Bound C4d, a Biomarker for Systemic Lupus Erythematosus
Richard Furie¹, Anca D. Askanase², Kenneth Kalunian³, Elena Massarotti⁴, Rosalind Ramsey-Goldman⁵, Daniel J Wallace⁶, Stuart L. Silverman⁷, Smitha Reddy⁸, Puja Chitkara⁹, Chaim Putterman¹⁰, Christopher Collins¹¹, Jill P. Buyon¹², Cristina Arriens¹³, Tyler O'Malley¹⁴, Roberta Alexander¹⁵, Derren Barken¹⁶, John Conklin¹⁷, Susan Manzi¹⁸, Joseph Ahearn¹⁹, Arthur Weinstein²⁰ and Thierry Dervieux¹⁴, ¹North Shore University Hospital, Great Neck, NY, ²Medicine, Rheumatology, Columbia University Medical Center, New York, NY, ³Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, ⁴Rheumatology, Immunology, & Allergy, Harvard Medical School, Brigham & Women's Hosp, Boston, MA, ⁵FSM, Northwestern University, Chicago, IL, ⁶Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Cedars, Beverly Hills, CA, ⁸Arthritis Care and Research Center, Inc., Poway, CA, ⁹Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA, ¹⁰Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ¹¹MedStar Washington Hospital Center, Washington, DC, ¹²Medicine, New York University School of Medicine, New York, NY, ¹³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Research and Development, Exagen Diagnostics, Vista, CA, ¹⁵Research & Development, Exagen Diagnostics, Vista, CA, ¹⁶Exagen Diagnostics, Vista, CA, ¹⁷1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ¹⁸Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁹Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA, ²⁰Rheumatology Section, Washington Hospital Center, Washington, DC
Background/Purpose: Previous studies have established the value of measuring complement activation products (C4d) bound to platelets (PC4d) for the diagnosis and monitoring of Systemic Lupus…
Abstract Number: 786 • 2016 ACR/ARHP Annual Meeting
Complement Split Product iC3b and C3 Blood Levels Best Associate with Active and Clinically Meaningful Changes in SLE Disease Activity
Alfred Kim¹, Deepali Sen², Vibeke Strand³, Qiang John Fu⁴, Nancy Mathis¹, Robin Bruchas⁵, Nick Staten⁵, Martin Schmidt⁶, Paul Olson⁵, Chad Stiening⁵ and John Atkinson¹, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, ³Stanford University School of Medicine, Palo Alto, CA, ⁴Biostatistics, Saint Louis University, Saint Louis, MO, ⁵Kypha, Inc., Saint Louis, MO, ⁶Kypha, Inc., St. Louis, MO
Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…
Abstract Number: 743 • 2015 ACR/ARHP Annual Meeting
Behavior of Complement Levels and Risk of Organ Involvement in SLE Patients
Ignacio Javier Gandino¹, Marina Scolnik¹, Emmanuel Bertiller¹, Valeria Scaglioni² and Enrique R. Soriano³, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology, Hospital Italiano, Buenos Aires, Argentina, ³Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: the complement system plays a major role in autoimmune diseases, and in particular in systemic lupus erythematosus (SLE). Complement deficiencies are a genetic risk factor for SLE.…
Abstract Number: 767 • 2015 ACR/ARHP Annual Meeting
Estimating the Pre-Test Probability of Systemic Lupus Erythematosus By Utilizing Anti-Double Stranded DNA and Cell Bound Complement Activation Products Testing from Rheumatology Based Practices in the United States
Stuart L. Silverman¹, Derren Barken², John Conklin³, Claudia Ibarra⁴ and Thierry Dervieux⁵, ¹OMC Clinical Research Center, Beverly Hills, CA, ²Exagen Diagnostics, Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴Clinical Laboratory, Exagen Diagnostics, Vista, CA, ⁵Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose : Clinicians are aware that the interpretation of any clinical diagnostic test and post-test probability of disease is highly influenced by pre-test probability or…
Abstract Number: 770 • 2015 ACR/ARHP Annual Meeting
Circulating Levels of iC3b and C3 Correlate with Sledai-2K Responder Index-50 (S2K RI-50) Disease Activity Scores: The Castle (Complement Activation Signatures in Systemic Lupus Erythematosus) Study
Alfred Kim¹, Vibeke Strand², Nancy Mathis¹, Deepali Sen³, Jonathan Miner³, Elizabeth Schramm¹, Robin Bruchas⁴, Nick Staten⁴, Paul Olson⁴, Chad Stiening⁴ and John Atkinson¹, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ³Division of Rheumatology, Washington University School of Medicine, Saint Louis, MO, ⁴Kypha, Inc., Saint Louis, MO
Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…
Abstract Number: 1921 • 2014 ACR/ARHP Annual Meeting
The Deposition of Complement C4d Split Product on Platelets and Erythrocytes Correlate with Disease Activity and Improvement in Systemic Lupus Erythematosus
Joan T. Merrill¹, Aikaterini Thanou², Stan Kamp¹, John Conklin³, Derren Barken⁴ and Thierry Dervieux⁵, ¹Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ⁴Exagen Diagnostics, Inc., Vista, CA, ⁵rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: We sought to evaluate the usefulness of cell bound complement activation products (C4d deposition on erythrocytes [EC4d] and platelets [PC4d]) in the monitoring of…
Abstract Number: 1631 • 2014 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products and Their Relationship to Disease Activity and Quality of Life Measures in Systemic Lupus Erythematosus
Richard Furie¹, Jill P. Buyon², R. Ramsey-Goldman³, Chaim Putterman⁴, Kenneth Kalunian⁵, Tyler O'Malley⁶, John Conklin⁷, Derren Barken⁸ and Thierry Dervieux⁹, ¹Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵UCSD School of Medicine, La Jolla, CA, ⁶Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁷1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ⁸Exagen Diagnostics, Inc., Vista, CA, ⁹rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: To assess the association between cell bound complement activation products (CBCAPS) and measures of disease activity and quality of life in systemic lupus erythematosus…
Abstract Number: 2525 • 2013 ACR/ARHP Annual Meeting
An Assay Panel Combining Cell Bound Complement Activation Products With Autoantibodies To Extractable Nuclear Antigens and Mutated Citrullinated Vimentin Helps With The Differential Diagnosis Of Systemic Lupus Erythematosus
Chaim Putterman¹, Richard Furie², R. Ramsey-Goldman³, Anca Askanase⁴, Jill P. Buyon⁵, Kenneth C. Kalunian⁶, W. Winn Chatham⁷, Elena M. Massarotti⁸, Emily C. Somers⁹, Irene Blanco¹⁰, Puja Chitkara¹¹, Nicole Jordan¹², Kyriakos A. Kirou¹³, Arthur Weinstein¹⁴, Susan Manzi¹⁵, Joseph M. Ahearn¹⁶, Claudia Ibarra¹⁷, Derren Barken¹⁸ and Thierry Dervieux¹⁹, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²North Shore-LIJ Health System, Lake Success, NY, ³Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴NYU School of Medicine, New York, NY, ⁵Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁶UCSD School of Medicine, La Jolla, CA, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁹IntMed, Environmental Health, and OB/GYN, University of Michigan, Ann Arbor, MI, ¹⁰Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ¹¹Rheumatology, SDAMC, San Diego, CA, ¹²Department of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ¹³Hospital for Special Surgery, New York, NY, ¹⁴Washington Hospital Center, Washington, DC, ¹⁵Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ¹⁶Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁷Clinical Laboratory, Exagen Diagnostics, Vista, CA, ¹⁸Exagen Diagnostics, Vista, CA, ¹⁹Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose: We previously established the value of cell-bound complement activation products (CBCAPS) in the diagnosis of systemic lupus erythematosus (SLE) (CAPITAL study). The purpose of…
Abstract Number: 1580 • 2013 ACR/ARHP Annual Meeting
Drug-Resistant Bloodstream Infections In Systemic Lupus Erythematosus Patients: A Clinical Perspective
Ana Barrera-Vargas¹, Diana Gómez-Martín¹, Alfredo Ponce de León² and Jorge Alcocer-Varela¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Infectology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Infections are an important cause of mortality and morbidity in Systemic Lupus Erythematosus (SLE) patients. Different risk factors have been described for the development…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].